Table 1.

Comparisons of baseline characteristics between short- and long-term survivors.

Variables	All (n=211)	STS (n=167)	LTS (n=44)	P value
Age at diagnosis (years)	49.0 ± 11.8	49.9 ± 11.3	41.2 ± 11.1	<0.001
Gender				0.432
Male	126/211	102/167	24/44
KPS score	80.0 ± 14.2	76.2 ± 14.9	82.2 ± 8.3	0.002
Tumor size (mm)	49.2 ± 18.9	49.5 ± 19.1	48.1 ± 18.3	0.652
Tumor location				0.039*
Frontal	86/211	60/167	26/44
Temporal	56/211	45/167	11/44
Parietal	35/211	32/167	3/44
Occipital	18/211	16/167	2/44
Others	16/211	14/167	2/44
Laterality				0.138
Right	92/211	67/167	25/44
Left	95/211	80/167	15/44
Bilateral	24/211	20/167	4/44
Enhancement				0.139
Solid	144/211	118/167	26/44
Ring	38/211	30/167	8/44
Irregular	29/211	19/167	10/44
Cystic change				<0.001
Yes	57/211	32/167	25/44
Extent of resection				<0.001
GTR	91/211	53/167	38/44
Chemotherapy				0.084
Temozolomide	170/211	134/167	36/44
Nimostine	27/211	19/167	8/44
None	14/211	14/167	0/44
Radiotherapy				0.005*
Yes	188/211	144/167	44/44
Recurrence pattern				0.838
Local	156/195	134/167	22/28
MGMT promotor				<0.001
Methylation	68/160	44/126	24/34
IDH				<0.001
Mutation	55/211	28/167	27/44
1q/19p co-polysomy				0.047
Yes	30/202	21/167	9/35
Ki-67 index				0.510
High	70/193	59/158	11/35

KPS, Karnofsky performance scale; GTR, gross-total resection; MGMT, O⁶-methylguanine-DNA-methyltransferase; IDH, isocitrate dehydrogenase.

*by Fisher exact test.